TP53 and renal cell carcinoma: Based on the finding that TGase 2 inhibition increases p53 stability, we also tested the possibility that DNA-damaging reagents such as doxorubicin expand the damage of p53-mediated cell death when combined with TGase 2 inhibition in a preclinical model of RCC.